MON-335 - Ultrasensitive bio-recognition and bio-imaging via in situ bio-responsive self-assembling nanoclusters and electrochemical nanointerface

The ultrasensitive biorecognition for the early diagnosis / monitoring of some important disease like cancers has attracted much attention in the relevant fields. In this study, we have explored the possibility of the application of some biomolecular probes combining with the bio-responsive self-assembly supramolecules or nano-scaled agents in targeting bio-recognition and high-sensitive biosensing / bioimaging of the diseased locations like tumors. Especially, we have developed some novel strategies for the rapid imaging and highly sensitive recognition of the targeted biomolecules and cancer cells / exosomes by combining the active agents and functionalized nanointerfaces for multiscale theranostics. Our observations demonstrate that the in situ self-assembly of the specific biomolecules with the nano-probes could provide a multifunctional interface for the rapid identification and precise imaging of cancer cells / exosomes, with a broad detection range and low detection limit. It is evident that different types of cancer cells or relevant bacteria can be readily distinguished on the bio-responsive spectra-electrochemical nano-interfaces, which have the promising application to be adopted as a significant way to detect various kinds of mutant cells / tissues or related exosomes in vivo and advance the clinic diagnosis and treatment of some important diseases like cancers. Moreover, some ultrasensitive and intelligently multi-functional nanoscale bio-robots based on the in vivo bio-responsive self-assembly of bio-synthetic nanoclusters through utilizing the peculiarities of the microenvironment and relevant redox homeostasis from cancer cells or bacteria have been also explored for the real-time multi-scale monitoring and multi-modality / or panoramic imaging of cancer cells and relevant exosomes as well as affected tissues for precise theranostics.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*